PerkinElmer, Inc. PKI
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 14.46B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.24%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 19.83
- Beta
- 1.10
- Short ratio
- 5.07
- Inst. own
- 86.25%
- Dividend
- 0.28
- Ex-div date
- Jul 19, 2023
- Earnings
- May 11, 2023
- 50-d avg
- 127.44
- 200-d avg
- 131.99
- 1y target
- 149.71
3M chart
Events in this range
- Apr 20, 2023Dividend: 0.07
- May 11, 2023Earnings: —; estimate 0.99; surprise —%
- May 12, 2023Rating: Barclays · Equal-Weight → Equal-Weight
- May 12, 2023Rating: Baird · Outperform → Outperform
- May 12, 2023Rating: Stifel · Hold → Hold
- May 15, 2023Rating: Citigroup · Buy → Buy
Signals (13)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | May 11, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 3, 2023 | 3 years ago |
| SMA: Bearish | May 2, 2023 | 3 years ago |
| SMA: Bullish | Apr 28, 2023 | 3 years ago |
| SMA: Bearish | Apr 27, 2023 | 3 years ago |
| SMA: Bullish | Apr 26, 2023 | 3 years ago |
| SMA: Bearish | Apr 25, 2023 | 3 years ago |
| SMA: Bearish | Apr 25, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 21, 2023 | 3 years ago |
| SMA: Bullish | Mar 30, 2023 | 3 years ago |
| SMA: Bullish | Mar 24, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 16, 2023 | 3 years ago |
Key statistics
- Market cap
- 14.46B
- Enterprise value
- 18.58B
- Trailing P/E
- 41.45
- Forward P/E
- 19.83
- PEG ratio
- -8.28
- Price / sales
- 4.36
- Price / book
- 1.97
- EPS (TTM)
- 2.78
- Beta
- 1.10
- Dividend yield
- 0.24%
- Payout ratio
- 10.00%
- Profit margin
- 17.19%
- Revenue (TTM)
- 3.31B
- Revenue growth
- -27.90%
- Free cash flow
- -262.12M
- Total cash
- 454.36M
- Total debt
- 4.60B
- Return on equity
- 7.06%
- Shares outstanding
- 125.44M
- Short % of float
- 3.57%
- 50-day average
- 127.44
- 200-day average
- 131.99
Analyst view
Consensus: buy
- Target (low)
- 125.00
- Target (mean)
- 149.71
- Target (high)
- 185.00
- Strong buy3
- Buy2
- Hold7
- Sell2
- Strong sell0
Next earnings
May 11, 2023
Expected May 11, 2023. Consensus EPS estimate 1.23.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 11, 2023 | Mar 1, 2023 | 0.99 | — | — | — |
| Feb 14, 2023 | Dec 1, 2022 | 1.66 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | 1.48 | — | — | — |
| Aug 1, 2022 | Jun 1, 2022 | 2.03 | — | — | — |
| May 3, 2022 | Mar 1, 2022 | 2.08 | — | — | — |
| Feb 1, 2022 | Dec 1, 2021 | 2.15 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 15, 2023 | Citigroup | main | Buy | Buy |
| May 12, 2023 | Stifel | main | Hold | Hold |
| May 12, 2023 | Baird | main | Outperform | Outperform |
| May 12, 2023 | Barclays | main | Equal-Weight | Equal-Weight |
| Feb 15, 2023 | Credit Suisse | reit | — | Neutral |
| Feb 15, 2023 | Baird | main | — | Outperform |
About PerkinElmer, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- perkinelmer.com
News
- Earnings Scheduled For May 11, 2023
- Earnings Scheduled For March 2, 2023
- Earnings Scheduled For February 14, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
- Earnings Scheduled For November 8, 2022
- Earnings Scheduled For November 2, 2022
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
Your note
Sign in to keep a note on PKI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOLDBERG JOEL S | General Counsel | Stock Award(Grant) | Feb 15, 2023 | 94,596 |
| KRAKOWIAK MAXWELL | Chief Financial Officer | Sale | Mar 28, 2023 | 7,202 |
| MCMURRY-HEATH MICHELLE | Director | Stock Award(Grant) | Aug 14, 2022 | 1,058 |
| MICHAS ALEXANDROS P | Director | Stock Gift | Aug 23, 2022 | 0 |
| MOCK JAMES M | Chief Financial Officer | Sale | Jun 23, 2022 | 27,577 |
| OKUN ANDREW | Officer and Treasurer | Sale | Apr 12, 2023 | 4,364 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 11.61% | 14,677,742 | 1.69B | Mar 30, 2023 |
| Capital Research Global Investors | 9.37% | 11,841,443 | 1.36B | Mar 30, 2023 |
| T. Rowe Price Investment Management, Inc. | 7.88% | 9,967,033 | 1.15B | Mar 30, 2023 |
| Select Equity Group, Inc. | 7.86% | 9,936,414 | 1.15B | Mar 30, 2023 |
| Blackrock Inc. | 6.79% | 8,579,355 | 988.68M | Mar 30, 2023 |
| State Street Corporation | 4.10% | 5,187,226 | 597.78M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Capital Appreciation Fund | 4.65% | 5,883,026 | 677.96M | Dec 30, 2022 |
| Amcap Fund | 4.28% | 5,415,726 | 624.11M | Mar 30, 2023 |
| Vanguard Total Stock Market Index Fund | 3.04% | 3,838,745 | 442.38M | Dec 30, 2022 |
| Vanguard Mid-Cap Index Fund | 2.33% | 2,942,444 | 339.09M | Dec 30, 2022 |
| Vanguard 500 Index Fund | 2.31% | 2,918,028 | 336.27M | Dec 30, 2022 |
| Growth Fund Of America Inc | 1.68% | 2,122,051 | 244.55M | Mar 30, 2023 |